To propose a protocol for minimizing medical complications associated with the use of cyproterone, medroxyprogesterone, and depot leuprolide to treat paraphilia.
Method
Review of the relevant literature.
Results
Certain patient populations should not be treated with these medications, and medical complications associated with each can be detected early and avoided.
Conclusions
For each drug, a series of screening tests prior to use and scheduled testing during use can minimize potential medical complications.
JacksonGLKuehlDRhimTJ. Testosterone inhibits gonadotropin-releasing hormone pulse frequency in the male sheep. Biol Reprod1991;24:188–94.
4.
SantenRJDemersLMMaxDTSmithJSteinBSGlodenLM. Long term effects of administration of a gonadotropin releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab1984;55:397–403.
5.
GellerJ. Overview of enzyme inhibitors and anti-androgen in prostatic cancer. J Androl1991;12:364–70.
6.
KappyMStuartTPerelmanAClemonsR. Suppresion of gonadotropin secretion by a long acting gonadotropin releasing hormone analog (leuprolide acetate, lupron depot) in children with precocious puberty. J Clin Endocrinol Metab1989;69:1087–9.
7.
McEvoyG, editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists; 1999.
8.
NeumannFKalmusJ. Cyproterone acetate in the treatment of sexual disorders: Pharmacological base and clinical experience. Experimental and Clinical Endocrinology1991;98(2):71–80.
9.
Bezchlibnyk-ButlerKZJeffriesJJ, editors. Clarke Institute handbook of clinical psychopharmacology. 6th ed.Toronto: Hogrefe and Huber; 1996.
10.
ConnPMCrowleyWFJr., Gonadotropin-releasing hormone and its analogues. N Engl J Med1990;324:93–103.
11.
ThibautFCordierBKuhnJM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand1993;87:445–50.
12.
RosierAWitztumE. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med1998;338:416–22.
13.
CooperAJSandhuSLosztynSCernovskyZ. A double-blind placebo controlled trial of medroxyprogestersone acetate and cyproterone acetate with seven pedophiles. Can J Psychiatry1992;37:687–93.
14.
RaoMVRoyGKPrasannalataSN. Effect of medroxyprogesterone acetate and testosterone enanthate on vas deferens of rats. Indian J Exp Biol1998;36:157–61.
15.
AvariKMBhiwgadeDA. Effect of depot medroxyprogesterone acetate and testosterone anathate on the testis of albino rats: Ultrastructural and biochemical studies. Indian J Exp Biol1992;30:1118–27.
16.
VallisKWaxmanJ. Tumour flare in hormone therapy. In: StrollBA, editor. Endocrine management of cancer. 2: Contemporary therapy. Basel (Switzerland): Karger; 1988. p 144–52.
17.
MorsiAJamalSSilverbergJDH. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clin Endocrinol1996;44:121–4.
18.
de VoogtHJSmithPHPavone-MacalusoMde PauwMSuciuS. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol1986;135:303–7.
19.
PierceEJ. Angina pectoris and myocardial infarction with the use of leuprolide acetate. Am J Obstet Gynecol1995;172(4 Pt 1):1323.
20.
Canadian Pharmaceutical Association. Compendium of pharmaceutical and specialties. Ottawa: Canadian Pharmaceutical Association; 1996.
21.
SarukiKSekiharaTMashimoMMatsuoHSekiguchiH. Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer. Prostate1998;34:191–4.
22.
StrumSBMcDermedJEScholzMCJohnsonHTismanG. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol1997;79:933–41.
23.
RoilaFCrinoLCarloniGNataliniG. Cyproterone acetate: Hepatotoxicity and prostate cancer treatment. Ann Oncol1993;4:701.
24.
ParysBTHamidSThomsonRG. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol1991;67:312–3.
25.
SmithJA. A prospective comparison for symptomatic hot flashes following endocrine therapy for carcinoma of the prostate. J Urol1994;152:132–4.
26.
SchotLPCSchuursAHWM. Pathophysiology of bone loss in castrated animals. J Steroid Biochem Mol Biol1990;37:461–5.
27.
StepanJJLachmanMZverinaJPacovskyVBaylinkDJ. Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodelling. J Clin Endocrinol Metab1989;69:523–7.
28.
LiMJeeWSKeHZTangLYMaYF, Liang XG, and others. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats. J Bone Miner Res1995;10:66–73.
29.
SchotLPSchuursAH. Sex steroids and osteoporosis: Effects of deficiencies and substitute treatments. J Steroid Biochem Mol Biol1990;37:167–88.
30.
JacksonJAMichaelK. Osteoporosis in men: Diagnosis, pathophysiology, and prevention. Medicine1990;69:137–52.
31.
SotaniemiEAHynnynenTAhlqvistJAhokasJTPuoskariUPelkonenI. Effects of medroxyprogesterone on the liver function and drug metabolism of patients with biliary cirrhosis and chronic active hepatitis. J Med1978;9:117–28.
32.
RautioASotaniemiEAPelkonenOLuomaPV. Treatment of alcoholic cirrhosis with enzyme inducers. Clin Pharmacol Ther1980;28:629–37.
33.
AbramsonFPMooreCFSrHillMD. Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein in beagle dogs. Research Communications in Chemical Pathology and Pharmacology1986;53:65–78.
34.
GotzVPDollyFRBlockAJ. Influence of medroxyprogesterone on theophylline disposition. J Clin Pharmacol1983;23:281–4.
